Login to Your Account



In The Clinic NEWS

Interim results from the open-label phase I/II study of BMN 270, Biomarin Pharmaceutical Inc.’s gene therapy to treat severe hemophilia A, showed the candidate outperformed expectations both in terms of efficacy and clinical improvements.

LMTX TO FLOWER IN FTD TRIAL?

A site investigator in the failed phase III study by Taurx Therapeutics Ltd. told BioWorld Today that Alzheimer's disease (AD) "absolutely" will best be attacked by a combination approach, despite the finding that tau aggregation blocker LMTX when used along with the standard, "modestly" beneficial AD drugs "doesn't add any value."

Tokai Pharmaceuticals Inc. called off a pivotal phase III trial comparing its triple-acting prostate cancer drug, galeterone, to Xtandi (enzalutamide, Medivation Inc.) after a data monitoring committee determined the trial was unlikely to meet its primary endpoint.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: